Summarized by Masters of Longevity from Longevity Technology.
Zervimesine-focused biotech developments: a patent milestone and near-term regulatory and manufacturing steps in support of a Lewy body dementia registrational program.
Key Takeaways
- A newly patented crystalline polymorph of zervimesine gives patent protection in the United States through 2045, strengthening commercial exclusivity prospects for the drug candidate.
- Cognition Therapeutics plans an FDA meeting to finalize DLB trial endpoints and aims to begin manufacturing the patented form in early 2027 for its registrational study.
- Zervimesine has completed multiple Phase 2 studies and showed efficacy signals in DLB, but its clinical benefit and approval remain unproven until late-stage trials confirm results.
